 |
620 Diseases |  |
1125 Trials |
|
1125 Trials |  |
32977 News |  |
| «12...56789101112131415...414415» |
- | Avastin (bevacizumab) / Roche
New P2 trial: Phase II randomized controlled clinical study of the efficacy and safety of bevacizumab in neoadjuvant chemotherapy for epithelial ovarian cancer (EUDRACT) - Sep 20, 2024
P2, N=60, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital
- | Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Prospective, Single-Arm, Phase II Clinical Study of Adebelizumab in Combination with Bevacizumab and Chemotherapy for EGFR-Mutated Recurrent or Metastatic NSCLC (EUDRACT) - Sep 20, 2024
P2, N=29, Not yet recruiting, Sponsor: Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: An open, multicenter, single arm clinical study on the combination of doxorubicin liposomes and CapOX/bevacizumab regimen for first-line treatment of advanced colorectal adenocarcinoma with SMAD4R361H/C mutation (EUDRACT) - Sep 20, 2024
P2, N=13, Not yet recruiting, Sponsor: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University
- | Avastin (bevacizumab) / Roche
New P2 trial: Cryoablation combined with PD-1 antibody and Bevacizumab for hepatocellular carcinoma after progression of PD-1/L1 antibody treatment: a pilot clinical study (EUDRACT) - Sep 20, 2024
P2, N=36, Not yet recruiting, Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
- | New P2 trial: B2024-428-01: Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment (clinicaltrials.gov) - Sep 19, 2024
P2, N=70, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Avastin (bevacizumab) / Roche
New P2/3 trial: Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin (clinicaltrials.gov) - Sep 19, 2024
P2/3, N=52, Recruiting, Sponsor: Isfahan University of Medical Sciences
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion, Trial completion date, Combination therapy: Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2024
P2, N=53, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024
- || Avastin (bevacizumab) / Roche, NP137 / NETRIS Pharma, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: Liver-NET1: Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (clinicaltrials.gov) - Sep 19, 2024
P1, N=52, Recruiting, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024 Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026
- |||| Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Hepatic chemoembolization in patients with liver metastases of colorectal origin. Quimioembolizaci (EUDRACT) - Sep 19, 2024
P2, N=126, Ongoing, Sponsor: Grupo Espa
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New trial, Metastases: ATBEST: Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=33, Recruiting, Sponsor: Yonsei University
- |||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Sep 19, 2024
P3, N=554, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026 Active, not recruiting --> Recruiting
- ||| SSGJ-707 / 3SBio
Enrollment open, Metastases: A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 19, 2024
P2, N=130, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: FOBEAR: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 19, 2024
P3, N=500, Recruiting, Sponsor: Yanhong Deng
Not yet recruiting --> Recruiting Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: IMPROVEMENT-2: Irinotecan Hydrochloride Liposome Injection (?) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2024
P2, N=75, Recruiting, Sponsor: Shanghai Changzheng Hospital
- || Retrospective data, Review, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. (Pubmed Central) - Sep 18, 2024
For patients with positive PD-L1 expression, Sin?+?CT and Cam?+?CT were found to be optimal for OS and PFS, respectively. It is important to note that, with the exception of Tor?+?CT, the toxicity of the other combinations was higher than that of CT alone.
- || Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
P2 data, Journal: Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. (Pubmed Central) - Sep 18, 2024
P2
It is important to note that, with the exception of Tor?+?CT, the toxicity of the other combinations was higher than that of CT alone. Sintilimab plus bevacizumab combined with radiotherapy provides favorable treatment response and survival outcomes along with an acceptable safety profile in the first-line setting for patients with HCC with PVTT (ClinicalTrials.gov Identifier: NCT05010434).
- || Avastin (bevacizumab) / Roche
P2 data, Journal, Metastases: Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial. (Pubmed Central) - Sep 17, 2024
The combination of bevacizumab and erlotinib as switch maintenance improves progression-free survival with an acceptable safety profile compared with active surveillance in patients with advanced BTCs in this phase II study. The trial moves on to the phase III component to evaluate improvement in overall survival.
- | galunisertib (LY2157299) / Eli Lilly, Avastin (bevacizumab) / Roche
Journal: Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation. (Pubmed Central) - Sep 17, 2024
and vascular endothelial growth factor by downregulating LAMC2. Correlation analysis of MRI data and pathological indicators showed that there was a good correlation between them.
- Avastin (bevacizumab) / Roche, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1174;
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Multicenter phase 2 trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04) (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1157;
- Sulanda (surufatinib) / Hutchmed, Avastin (bevacizumab) / Roche
Efficacy and safety of concurrent bevacizumab in combination with standard radiotherapy and temozolomide followed by bevacizumab in combination with temozolomide and surufatinib in glioblastoma: A phase 2 clinical trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1059;
- Avastin (bevacizumab) / Roche, Tagrisso (osimertinib) / AstraZeneca
Osimertinib combined with bevacizumab and chemotherapy as first-line treatment in EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1018;
- Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche
3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_945;
- Avastin (bevacizumab) / Roche, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_939;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Exploratory Biomarker Analysis in EGFR mutated NSCLC Patients who treated with Atezolizumab plus Bevacizumab and Chemotherapy from Phase III ATTLAS trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_924;
- Avastin (bevacizumab) / Roche, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Chemotherapy and Bevacizumab Induction Therapy Followed by Maintenance Therapy with Adebrelimab Plus Fluzoparib and Bevacizumab in Platinum-Sensitive Relapsed Ovarian Cancer (CHANGCHUN): A Single-Arm, Exploratory Study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_723;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Tumor response at the time of discontinuation of atezolizumab plus bevacizumab (Ate+Beva) predict progression free survival of patients who stop Ate+Beva therapy. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_588;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Combined Atezolizumab and Bevacizumab versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Single Center Experience (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_580;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Can the blood coagulation factor, von Willebrand factor, be a predictor of response to atezolizumab plus bevacizumab combination therapy for advanced hepatocellular carcinoma? (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_564;
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Atezolizumab plus bevacizumab versus Lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma: a large real-life worldwide population (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_555;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_553;
- Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: a single-arm, phase II study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_552;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Final Analysis of the ELIXIR Study: A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Atezolizumab + Bevacizumab (Atezo+Bev) in Japanese Patients with Unresectable Hepatocellular Carcinoma (uHCC) in a Real-World Clinical Setting (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_545;
- Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
Impact of baseline tumour burden on outcomes in EMERALD-1: a Phase 3 study of durvalumab (D) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_544;
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Real world experience with Trifluridine (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_465;
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
TAS-102 (trifluridine/tipiracil) plus Bevacizumab versus TAS-102 alone as Salvage Treatment Options for Metastatic Colorectal Cancer in Routine Clinical Practice (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_459;
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Analysis of Prognostic Factors on Trifluridine-Tipiracil Plus Bevacizumab Treatment in Metastatic Colorectal Cancer: A Retrospective Real-World Analysis (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_453;
- Avastin (bevacizumab) / Roche
Liposomal irinotecan + 5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): a prospective, multi-center, single-arm clinical study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_450;
- Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line chemotherapy for metastatic colorectal cancer in the real-world (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_447;
- Avastin (bevacizumab) / Roche
Impact of renal impairment on chemotherapy-induced neutropenia in patients who are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for metastatic colorectal cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_440;
- Avastin (bevacizumab) / Roche
Erlotinib plus Bevacizumab in Patients with metastatic solid tumors with EGFR amplification: Results from the KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL 22-09) (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_294;
- Avastin (bevacizumab) / Roche
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKET?): A Prospective, Single-Arm, Open-Label, Phase II Study (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_216;
- | Avastin (bevacizumab) / Roche
Journal: Association of Retinal Thickness at Month 1 Post-Treatment with Later Thickness and Visual Acuity in Central Vein Occlusion. (Pubmed Central) - Sep 15, 2024
Correlation analysis of MRI data and pathological indicators showed that there was a good correlation between them. Having a post-treatment thin retina can be as detrimental to visual acuity as a post-treatment thick retina.
- | Avastin (bevacizumab) / Roche
Journal: QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. (Pubmed Central) - Sep 15, 2024
P2
Having a post-treatment thin retina can be as detrimental to visual acuity as a post-treatment thick retina. CAPOXIRI+BEV was well tolerated with reduced hematological toxicity and efficacy comparable to those of FOLFOXIRI+BEV, providing a potentially convenient first-line treatment alternative to FOLFOXIRI+BEV in patients with mCRC.
- ||| Hansizhuang (serplulimab) / Fosun Pharma
Clinical, P2/3 data, Journal, Metastases: First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial. (Pubmed Central) - Sep 15, 2024
P2/3
CAPOXIRI+BEV was well tolerated with reduced hematological toxicity and efficacy comparable to those of FOLFOXIRI+BEV, providing a potentially convenient first-line treatment alternative to FOLFOXIRI+BEV in patients with mCRC. Serplulimab plus HLX04 and XELOX exhibits promising efficacy and is safe and tolerable in patients with treatment-naive mCRC.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A New Self-Expandable Metallic Stent with Low Axial Force and a High Axial Force Zero-Border Shows a Very Low Perforation Rate in Malignant Colorectal Obstruction: A Japanese Multicenter Prospective Study. (Pubmed Central) - Sep 14, 2024
There were no fatal cases related to stent placement. For management of malignant colorectal obstruction, this newly developed SEMS with low axial force and a high axial force zero-border showed high technical and clinical success rates, and an extremely low perforation rate (0.5%).
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Sep 14, 2024
While a broad array of infections occurred in 50% of the patients in this cohort, it did not negatively impact survival outcomes. However, it did impact morbidity, with more all-cause admissions and treatment delays.
- || Review, Journal: Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies. (Pubmed Central) - Sep 14, 2024
This study provides comprehensive insights into effective treatment interventions for HCC in Asian populations. The overall assessment indicates that sorafenib, used alone or in combination with atezolizumab and bevacizumab, has been the first treatment choice in the past decade to achieve better outcomes in patients with HCC in Asian populations.
- | Avastin (bevacizumab) / Roche
Journal: Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study. (Pubmed Central) - Sep 14, 2024
The UPCR saves one unnecessary 24-h urine test for less than a dollar compared to a simple UD. The results indicate that using the UPCR could enhance diagnostic accuracy, lower costs, and reduce unnecessary 24-h urine sampling.
- | Avastin (bevacizumab) / Roche
Journal: Predicting prognosis for epithelial ovarian cancer patients receiving bevacizumab treatment with CT-based deep learning. (Pubmed Central) - Sep 14, 2024
Comparative analysis against FIGO staging revealed an NRI of 0.06 (P?<?0.001) for the multimodal model. The model presents opportunities for prognostic assessment, treatment strategizing, and ongoing patient monitoring.